🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#GSK, #BP, #MMM, #GLW, #MTSR

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #GSK 68.8x
2. #BP 35.4x
3. #MMM 26.0x
4. #GLW 25.5x
5. #MTSR 21.4x

#OptionFlow #OptionsTrading #Trading

Just In: ( NASDAQ: #MTSR ) Should You Forget Pfizer and Buy This Magnificent Drug Stock Instead?

NEWS: ( NASDAQ: #MTSR ) Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?

Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Deal

In late October, it was reported that Novo Nordisk was looking to acquire Metsera for $6.5 billion

#PFE #MTSR

Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior" Metsera (NASDAQ: B) announced its board has declared an amended acquisition proposal from Novo Nordisk a Superior Company Proposal under Metsera's merger agreement with Pfizer. Novo Nordisk's two-step proposal values Metsera at up to $86.20 per share (~$10.0B), including an immediate cash payment/dividend of $62.20 per share and a second-step contingent value right (CVR) of up to $24.00 per share. Metsera notified Pfizer, triggering a two-business-day negotiation period under the Pfizer Merger Agreement.

#B #MTSR #NOVO Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior"

www.stocktitan.net/news/B/metsera-receives-...

Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition Pfizer (NYSE: PFE) announced on October 31, 2025 that the U.S. Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Act for Pfizer’s pending acquisition of Metsera (NASDAQ: MTSR).The early termination satisfies the HSR Act regulatory review requirements for the proposed acquisition, which had a waiting-period expiry date of November 7, 2025. The transaction remains pending other closing conditions.

#PFE #MTSR Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition

www.stocktitan.net/news/PFE/pfizer-receives...

Halper Sadeh LLC Urges Shareholders of GES, MTSR, TGNA, CYBR to Explore Their Legal Rights Halper Sadeh LLC is encouraging shareholders of Guess?, Metsera, TEGNA, and CyberArk to contact them regarding potential legal rights and options related to recent corporate sales.

Halper Sadeh LLC Urges Shareholders of GES, MTSR, TGNA, CYBR to Explore Their Legal Rights #USA #New_York #Halper_Sadeh_LLC #GES #MTSR

💊 Novo Nordisk has made an unsolicited ~$6.5B bid for Metsera, with milestones that could lift the value further. The offer of ~$77.75/share tops Pfizer’s ~$70 bid. Metsera’s board is reviewing the proposal.

#MTSR is up ~20% premarket.

Metsera Receives Unsolicited Proposal from Novo Nordisk Novo Nordisk Proposal Values Metsera at up to $77.75 per Share, a Total of Approximately $9 Billion. In the first step, immediately following the signing of a definitive agreement, Novo Nordisk would pay Metsera $56.50 per Metsera common share in cash as well as certain amounts in respect of Metsera employee equity and transaction expenses.

#B #MTSR #NOVO Metsera Receives Unsolicited Proposal from Novo Nordisk

www.stocktitan.net/news/B/metsera-receives-...

🔊 New Being Exponential podcast out now

Topics:
- Buy the dip or bursting bubble?
- White House invests in #LAC. Who's next?
- HSBC's quantum bonds: a "Sputnik moment"
- ChatGPT Instant Checkout vs. eBay, #PYPL
- Genius/Clarity Act update
- Breakout charts: #INTC #FLNC #MTSR #DDD #ABAT

#PFE #CRSP #MTSR #a4240e1d-c7eb-4b70-95ea-3803b1b86dfe #investing

Origin | Interest | Match

BREAKING NEWS: ( NASDAQ: #MTSR ) Pfizer Just Reminded Investors Why You Should Never Count Its Stock Out

Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3 Metsera (NASDAQ:MTSR) announced positive Phase 2b results for MET-097i, their first-in-class ultra-long acting GLP-1 receptor agonist candidate. The VESPER-1 trial demonstrated impressive placebo-subtracted weight loss of up to 14.1% after 28 weeks, with individual responses reaching 26.5%. The drug showed potentially best-in-class tolerability with minimal side effects in the VESPER-3 trial, including only 13% nausea and 11% vomiting at the highest dose.The trials involved 239 participants in VESPER-1 and 268 subjects in VESPER-3, with doses ranging from 0.4mg to 1.2mg. Notably, the study achieved high retention rates with only 2.9% discontinuation in VESPER-1. Based on these positive results, Metsera plans to initiate Phase 3 trials in late 2025, positioning MET-097i as a potential monthly dosing option with dual-agonist-like efficacy.

#MTSR Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3

www.stocktitan.net/news/MTSR/metsera-report...

BREAKING NEWS: ( NASDAQ: #MTSR ) Down 55%, Should You Buy the Dip on Pfizer?

Just In: ( NASDAQ: #MTSR ) Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet?

📢 Stocks Trending NOW: #QUBT #ORCL #SNAP #ASTS #MTSR #QLGN #AGRI #PFE #OKLO #BOXL

Pfizer Reportedly Nears Metsera Acquisition Deal: PFE Stock Climbs In Monday Pre-Market - Invesco International Growth Focus ETF (BATS:MTRA), Eli Lilly (NYSE:LLY) Pfizer Inc. (NYSE: PFE) stock climbed 1.87% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. (NASDAQ: MTSR), a developer of anti-obesity drugs.

Pfizer Reportedly Nears Metsera Acquisition Deal: PFE Stock Climbs In Monday Pre-Market Pfizer Inc. (NYSE: PFE) stock climbed 1.87% in Monday pre-market amid reports that the company on the verge ...

#Large #Cap #LLY #MTRA #MTSR #News #NVO #PFE #Health #Care #LLY

Origin | Interest | Match

Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio Pfizer (NYSE:PFE) has announced a definitive agreement to acquire Metsera (NASDAQ:MTSR) in a deal valued at $47.50 per share in cash, representing an enterprise value of $4.9 billion. The deal includes a CVR worth up to $22.50 per share tied to clinical and regulatory milestones.The acquisition brings Pfizer four clinical-stage incretin and amylin programs targeting obesity and cardiometabolic diseases. Key assets include MET-097i, a weekly and monthly injectable GLP-1 receptor agonist in Phase 2, and MET-233i, a monthly amylin analog in Phase 1, along with two oral GLP-1 RA candidates.The transaction is expected to close in Q4 2025, subject to regulatory approvals and Metsera shareholder approval. This strategic move positions Pfizer in the growing obesity therapeutic area, which is associated with over 200 health conditions.

#PFE #MTSR Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio

www.stocktitan.net/news/PFE/pfizer-to-acqui...

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #STX 3.4x
2. #MCW 3.2x
3. #MRVL 2.5x
4. #MTSR 2.4x
5. #ANET 2.2x

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#MCW, #MTSR, #ANET, #EYE, #IONS

#OptionFlow #OptionsTrading #Trading

Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress Metsera (NASDAQ:MTSR), a clinical-stage biopharmaceutical company, reported significant progress in its Q2 2025 pipeline for obesity and metabolic disease treatments. The company highlighted positive results for two key programs: MET-097i, a monthly GLP-1 receptor agonist with Phase 3 initiation planned for late 2025, and MET-233i, a monthly amylin analog that achieved 8.4% weight loss in five weeks with a 19-day half-life.The company maintains a strong financial position with $530.9 million in cash, providing runway into 2027. Q2 2025 saw increased R&D expenses of $60.5 million and a net loss of $68.7 million. Multiple clinical milestones are expected in late 2025, including VESPER-1 data release, 12-week monotherapy data for MET-233i, and preliminary results from their oral peptide program.

#MTSR Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress

www.stocktitan.net/news/MTSR/metsera-report...

Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i Metsera (NASDAQ: MTSR) announced positive Phase 1 trial results for MET-233i, their first-in-class ultra-long acting amylin analog. The drug demonstrated impressive efficacy with up to 8.4% mean placebo-subtracted weight loss at Day 36 and a 19-day half-life supporting monthly dosing. The trial involved 80 participants with overweight/obesity, testing doses from 0.15mg to 2.4mg. Key findings include dose-linear pharmacokinetics, sustained weight loss effects, and favorable tolerability with no safety signals. The drug shows potential for combination with Metsera's GLP-1 receptor agonist MET-097i, positioning it as a possible first monthly multi-NuSH combination therapy. Based on these results, Metsera is advancing both monotherapy and combination trials, with additional data expected in late 2025 or early 2026.

#MTSR Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

www.stocktitan.net/news/MTSR/metsera-announ...

Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress Metsera (NASDAQ: MTSR) reported its Q1 2025 financial results and pipeline updates. The company's cash position stands at $588.3 million, supporting operations into 2027. Key financial metrics include R&D expenses of $57.2 million and a net loss of $76.6 million. Their lead candidate, MET-097i, a monthly GLP-1 receptor agonist, is progressing through three VESPER Phase 2b trials, with VESPER-1 data expected mid-2025. The company's pipeline includes MET-233i, a monthly amylin analog in Phase 1, and oral candidates MET-097o and MET-224o. Notable weight loss results of up to 14.2% were reported for MET-097i. The company successfully completed a $316 million IPO and appointed Jon P. Stonehouse as Director and Matthew Lang as Chief Legal Officer.

#MTSR Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress

www.stocktitan.net/news/MTSR/metsera-report...